BIOSYENT INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.6 CAD | +0.95% |
|
+3.23% | +4.12% |
| May. 17 | Tranche Update on BioSyent Inc. (TSXV:RX)'s Equity Buyback Plan announced on December 13, 2023. | CI |
| May. 17 | BioSyent Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Presenter SpeechRené Goehrum (Executives)Good morning. The meeting will now come to order. My ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Companyâs business marketing biologically and health friendly non-chemical insecticides. Its products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Cathejell combines sterile gel and 2% lidocaine jelly in a collapsible syringe that is ready to use. FeraMAX Pd Therapeutic 150 is an oral hematinic that helps the body form red blood cells and is indicated for the treatment of iron deficiency anemia.
Sector
Pharmaceuticals
Calendar
2024-08-19
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
9.6
CAD
Average target price
9.65
CAD
Spread / Average Target
+0.52%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.12% | 82.49M | |
| +52.93% | 803B | |
| +39.89% | 629B | |
| -7.08% | 351B | |
| +17.40% | 324B | |
| +10.58% | 303B | |
| +14.96% | 244B | |
| +1.60% | 226B | |
| +6.24% | 164B | |
| -4.79% | 155B |
- Stock Market
- Equities
- RX Stock
- News BioSyent Inc.
- Transcript : BioSyent Inc. - Shareholder/Analyst Call
